20 articles
A large multicenter study finds GLP-1 receptor agonists dramatically outperform DPP-4 inhibitors in preventing HCC recurrence and death post-resection.
GLP-1 receptor agonists may overcome Lenvatinib resistance in hepatocellular carcinoma by targeting a key glycolytic vulnerability.
New research reveals popular weight-loss medications may reduce cancer risk beyond their metabolic benefits.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
New research reveals how popular weight-loss medications could offer unexpected cancer protection benefits.
Large study reveals immune checkpoint inhibitors cause diabetes in 0.52% of patients, with 90% requiring hospitalization.
Researchers discover how SIRT6 protein overcomes temozolomide resistance in deadly brain cancer by modifying histone lactylation patterns.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
Scientists develop brain-penetrating drug that makes glioblastoma cells vulnerable to targeted elimination therapy.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-γ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Flaxseed compounds enhance PD-1 inhibitor effectiveness against breast cancer through gut bacteria modulation and immune system activation.
Researchers used advanced genetic analysis to find LGALS9 and SELL genes causally linked to aggressive brain tumors, revealing new treatment targets.
Comprehensive review reveals increasing GEP-NET incidence and advances in endoscopic diagnosis and targeted therapies for these diverse tumors.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Zanidatamab achieved 44% response rate in small study of patients with aggressive salivary gland tumors, offering new hope for rare cancer.
Tislelizumab plus anlotinib achieved promising results in treating advanced pulmonary sarcomatoid carcinoma with manageable side effects.
